Hematology | Topics

 
Higher-Risk MDS Satellite Symposium
May 20, 2022

Program chair Navel Daver, MD, invites you to PER®’s complimentary in-person and virtual satellite symposium.

Perspectives on COVID-19 Prophylaxis and Vaccination
May 19, 2022

To close the discussion, panelists reflect on their practices’ guidance on long-acting antibody prophylaxis and vaccination against COVID-19 for patients with graft-versus-host-disease (GVHD).

Alina Markova, MD, on Topical Ruxolitinib Mechanism of Action in Cutaneous Chronic GVHD
May 19, 2022

Alina Markova, MD, speaks to the mechanism of action of topical ruxolitinib INCB018424 phosphate 1.5% cream vs oral ruxolitinib and other topical therapies used in the treatment of non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.

Uday R. Popat, MD, Reviews Post-Transplant Cyclophosphamide Vs Tacrolimus and Methotrexate to Prevent GVHD in AML/MDS
May 18, 2022

Uday R. Popat, MD, spoke about how well post-transplant cyclophosphamide vs tacrolimus plus methotrexate to prevent graft-vs-host disease was performed in this trial.

Geriatric Consultation Did Not Significantly Improve Survival in Hematologic Malignancies But Increased End of Life Care Discussions
May 17, 2022

Geriatric consultations vs standard of care for patients with hematologic malignancies who were pre-frail or frail did not significantly improve survival at 1 year but did increase discussions on end-of-life goals of care.

Recap: Treatment Advances in Chronic GVHD
May 15, 2022

A panel of experts in stem cell transplant and cellular immunotherapy builds a lively discussion on current and emerging treatment options for the management of acute and chronic graft versus host disease.

Alina Markova, MD, on the Rationale for Assessing Topical Ruxolitinib in Cutaneous Chronic GVHD
May 13, 2022

Alina Markova, MD, discusses the rationale for assessing topical ruxolitinib INCB018424 phosphate 1.5% cream in patients with non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.

Treatment Approaches Using Ruxolitinib in GVHD
May 12, 2022

In a discussion on the use of ruxolitinib in GVHD, experts consider the potential role of dose reductions or dose holds to mitigate toxicity and comment on experiences with combining or sequencing therapies in later lines of treatment.

Additional Approaches for Steroid-Refractory Chronic GVHD
May 12, 2022

Expert panelists comment on additional treatment options for significant steroid-refractory chronic GVHD following initial therapeutic intervention, including rechallenging with prophylactic agents or initiating B-cell therapy.

Uday R. Popat, MD, Discusses Rationale for Post-Transplant Cyclophosphamide as GVHD Prophylaxis in AML/MDS
May 11, 2022

Uday R. Popat, MD, spoke about the decision to use post-transplant cyclophosphamide vs tacrolimus plus methotrexate to prevent graft-vs-host disease.